Palbociclib (PAL) plus letrozole (L) as first-line (1) therapy (tx) in estrogen receptor-positive (ER plus )/human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): Efficacy and safety across patient (pt) subgroups.

被引：6

作者：

Finn, Richard S.

Dieras, Veronique

Rugo, Hope S.

Joy, Anil A.

Moulder, Stacy L.

Walshe, Janice Maria

Mukai, Hirofumi

Shparyk, Yaroslav V.

Park, In Hae

Mori, Ave

Lu, Dongrui

Gauthier, Eric Roland

Gelmon, Karen A.

机构：

[1] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA

[2] Inst Curie, Paris, France

[3] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94143 USA

[4] Cross Canc Inst, Edmonton, AB, Canada

[5] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[6] CCRT, Dublin, Ireland

[7] Natl Canc Ctr Hosp East, Chiba, Japan

[8] Lviv State Oncol Reg Med & Diagnost Ctr, Lvov, Ukraine

[9] Natl Canc Ctr, Ctr Breast Canc, Goyangsi, South Korea

[10] Pfizer Srl, Milan, Italy

[11] Pfizer Inc, La Jolla, CA USA

[12] British Columbia Canc Agcy, Vancouver, BC, Canada

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷

关键词：

D O I：

10.1200/JCO.2017.35.15_suppl.1039

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1039

引用

页数：6

共 50 条

[21] Neoadjuvant nivolumab (NIVO) plus palbociclib (PALBO) plus anastrozole (ANA) for estrogen receptor-positive (ER plus )/human epidermal growth factor receptor 2-negative (HER2-) primary breast cancer (BC): CheckMate 7A8 [J].

Jerusalem, G. ;

Prat, A. ;

Salgado, R. F. ;

Reinisch, M. ;

Saura, C. ;

Ruiz Borrego, M. ;

Nikolinakos, P. ;

Filian, J. ;

Ades, F. ;

Huang, N. ;

Mazzei-Abba, A. ;

Tolaney, S. M. .

ANNALS OF ONCOLOGY, 2022, 33 :S165-S166

[22] Patient-reported quality of life in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer (ABC) treated with palbociclib (PAL) plus letrozole (LET): Results from PALOMA-4 [J].

Hu, X. ;

Broughton, E. ;

Li, W. ;

Sun, T. ;

Shen, K. ;

Huang, C. ;

Sriuranpong, V. ;

Ngan, K. C. R. ;

Chia, Y. H. ;

Bhattacharyya, H. ;

Zhao, H. ;

Shen, J. ;

Xu, B. .

ANNALS OF ONCOLOGY, 2022, 33 (07) :S637-S637

[23] Palbociclib (PAL) in male patients (pts) with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer (ABC): Pt characteristics and treatment (Tx) patterns from the POLARIS study [J].

Blum, J. L. ;

Dicristo, C. ;

Gordon, D. ;

Karuturi, M. ;

Oubre, D. ;

Jepsen, E. ;

Cuevas, J. ;

Lakhanpal, S. ;

Zhang, Z. ;

Drucker, M. ;

Wang, Y. ;

Tripathy, D. .

ANNALS OF ONCOLOGY, 2021, 32 :S68-S69

[24] Overall survival (OS) with palbociclib (PAL) plus fulvestrant (FUL) in women with hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): Updated analyses from PALOMA-3. [J].

Cristofanilli, Massimo ;

Rugo, Hope S. ;

Im, Seock-Ah ;

Slamon, Dennis J. ;

Harbeck, Nadia ;

Bondarenko, Igor ;

Masuda, Norikazu ;

Colleoni, Marco ;

DeMichele, Angela ;

Iwata, Sherene Loi Hiroji ;

O'Leary, Ben ;

Bananis, Eustratios ;

Liu, Yuan ;

Huang, Xin ;

Kim, Sindy ;

Lechuga, Mariajose ;

Turner, Nicholas C. .

JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)

[25] First-line ribociclib plus letrozole for postmenopausal women with hormone receptor-positive (HR+), HER2-negative (HER2-), advanced breast cancer (ABC) [J].

Hortobagyi, G. N. ;

Stemmer, S. M. ;

Burris, H. A. ;

Yap, Y. S. ;

Sonke, G. S. ;

Paluch-Shimon, S. ;

Campone, M. ;

Blackwell, K. ;

Andre, F. ;

Winer, E. P. ;

Janni, W. ;

Verma, S. ;

Conte, P. ;

Arteaga, C. L. ;

Cameron, D. ;

Xuan, F. ;

Souami, F. ;

Miller, M. ;

Germa, C. ;

O'Shaughnessy, J. .

ANNALS OF ONCOLOGY, 2016, 27

[26] Ribociclib plus letrozole in premenopausal patients with hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): Subgroup analysis of the phase IIIb CompLEEment-1 trial [J].

Razeq, Hikmat Abdel ;

Cottu, Paul ;

Ring, Alistair ;

De laurentiis, Michelino ;

Lu, Janice ;

Azim, Hamdy ;

Zamagni, Claudio ;

Zhou, Katie ;

Wu, Jiwen ;

Menon-Singh, Lakshmi ;

Martin, Miguel .

CANCER RESEARCH, 2021, 81 (04)

[27] Overall survival (OS) with palbociclib plus fulvestrant in women with hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): Analyses from PALOMA-3 [J].

Cristofanilli, M. ;

Slamon, D. J. ;

Ro, J. ;

Bondarenko, I. ;

Im, S-A. ;

Masuda, N. ;

Colleoni, M. ;

DeMichele, A. ;

Loi, S. ;

Verma, S. ;

Iwata, H. ;

Harbeck, N. ;

Loibl, S. ;

Andre, F. ;

Theall, K. Puyana ;

Huang, X. ;

Giorgetti, C. ;

Bartlett, C. Huang ;

Turner, N. C. .

ANNALS OF ONCOLOGY, 2018, 29

[28] Efficacy and safety of palbociclib plus endocrine therapy in North American women with hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer [J].

Gelmon, Karen A. ;

Cristofanilli, Massimo ;

Rugo, Hope S. ;

DeMichele, Angela M. ;

Joy, Anil A. ;

Castrellon, Aurelio ;

Sleckman, Bethany ;

Mori, Ave ;

Theall, Kathy Puyana ;

Lu, Dongrui R. ;

Huang, Xin ;

Bananis, Eustratios ;

Finn, Richard S. ;

Slamon, Dennis J. .

BREAST JOURNAL, 2020, 26 (03) :368-375

[29] Ribociclib (RIB) plus letrozole (LET) in subgroups of special clinical interest with hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): Subgroup analysis from the CompLEEment-1 trial [J].

Cottu, P. H. ;

Ring, A. ;

Marchetti, P. ;

Cardoso, F. ;

Salvador, J. ;

Neven, P. ;

Papazisis, K. ;

Campone, M. ;

Bachelot, T. ;

Menon-Singh, L. ;

Wu, J. ;

Zhou, K. ;

De laurentiis, M. .

ANNALS OF ONCOLOGY, 2020, 31 :S379-S380

[30] Overall survival of palbociclib (PAL) plus endocrine therapy (ET) in Japanese patients with hormone receptor-positive (HR plus )/human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC) in the 1st line (1L) or 2nd line (2L) setting: A multicenter observational study [J].

Nakayama, T. ;

Nagai, S. E. ;

Hattori, M. ;

Yoshinami, T. ;

Masuda, H. ;

Okamura, T. ;

Watanabe, K-I. ;

Tsuneizumi, M. ;

Takabatake, D. ;

Harao, M. ;

Yasojima, H. ;

Oshiro, C. ;

Iwase, M. ;

Yamaguchi, M. ;

Sangai, T. ;

Sasada, S. ;

Ishida, T. ;

Futamura, M. ;

Kosaka, N. ;

Masuda, N. .

ANNALS OF ONCOLOGY, 2024, 35 :S368-S368

← 1 2 3 4 5 →